TAVI Risk Score Calculator
FRANCE-2 risk-factor review
Review the published early-mortality predictors reported for patients undergoing TAVI. This checklist does not generate an individual mortality probability.
Clinical context
The FRANCE-2 early-mortality model was developed from 3,833 consecutive TAVI patients and predicted 30-day or in-hospital mortality. The published model identified nine predictors: age ≥90 years, BMI <30 kg/m², NYHA class IV, pulmonary hypertension, critical haemodynamic state, at least two pulmonary-oedema episodes in the preceding year, respiratory insufficiency, dialysis, and a transapical or other non-transfemoral approach.
The original publication derived a 21-point score. Its discrimination was moderate, with a C-index of 0.67 in the development cohort and 0.59 in the validation cohort. This implementation deliberately does not reproduce the point score because the source coefficients/point weights were not independently verified here.
Predictors represented in this checklist
| Predictor | Criterion represented |
|---|---|
| Age ≥90 years | Patient age is 90 years or older. |
| BMI <30 kg/m² | Body mass index below 30 kg/m². |
| NYHA class IV | Severe symptoms at rest or with minimal activity, consistent with NYHA class IV. |
| Pulmonary hypertension | Pulmonary hypertension documented in the clinical assessment. |
| Critical haemodynamic state | Critical haemodynamic status as defined by the original study. |
| ≥2 episodes of pulmonary oedema in the previous year | Two or more pulmonary-oedema episodes in the preceding 12 months. |
| Respiratory insufficiency | Respiratory insufficiency documented in the clinical assessment. |
| Dialysis | Patient is receiving dialysis. |
| Non-transfemoral access | Planned access is transapical or another non-transfemoral route. |
References
Clinical notes
Document key findings and keep a structured record for your own reference.
My notes
Review, edit, or remove notes saved in this browser.
Report an issue
Your feedback helps us improve the reliability and usability of this clinical tool.